Bexsero, meningitis B vaccine, receives FDA Breakthrough Therapy designation
PRESS RELEASE Novartis announced today that Bexsero® (Meningococcal Group B Vaccine [rDNA, component, adsorbed]) has received a Breakthrough Therapy designation from the United States Food and Drug Administration More...
UC Santa Barbara reports fourth case of meningococcal disease
A fourth University of California, Santa Barbara (UCSB) undergraduate student has been confirmed positive for meningococcal disease, according to a Santa Barbara County Public Health Department (PHD) press release More...
UC Santa Barbara freshman, Aaron Loy, has feet amputated due to meningococcal disease
The University of California, Santa Barbara meningitis outbreak affected three students in recent weeks, in which two have recovered and returned to school. However, one student, a lacrosse player from Carlsbad, More...
Princeton announces dates for receiving meningitis B vaccine
The New Jersey university, which has experienced eight cases of serogroup B meningococcal disease since March, has announced the dates they will be administering the vaccine that helps protect against meningococcal More...
FDA approves Menveo quadrivalent meningococcal vaccine in children starting as early as two months
The Food and Drug Administration (FDA) approved the expanded age range for Menveo quadrivalent meningococcal vaccine for infants and toddlers from 2 months of age, according to a FDA approval letter. Neisseria More...
Bexsero, first Meningitis B vaccine, receives European Commission approval
Photo/CDC/ Debora Cartagena Switzerland-based pharmaceutical and health care company, Novartis announced this week that it’s Meningitis B vaccine, Bexsero, has received approval from the European Commission More...
